Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prademagene zamikeracel - Abeona Therapeutics

Next Previous
Drug Profile

Prademagene zamikeracel - Abeona Therapeutics

Alternative Names: EB-101; Epidermolysis bullosa gene therapy - Abeona Therapeutics; Gene-corrected skin grafts - Abeona Therapeutics; LEAES; LZRSE COL7A1; LZRSE-Col7A1 Engineered Autologous Epidermal Sheets; Pz-cel; ZEVASKYN

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abeona Therapeutics
  • Class Cell therapies; Gene therapies; Skin disorder therapies
  • Mechanism of Action COL7A1 protein replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa dystrophica
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Epidermolysis bullosa dystrophica

Most Recent Events

  • 14 May 2025 Launched for Epidermolysis bullosa dystrophica (In adolescents, In children, In the elderly, In adults) in USA (Topical)
  • 12 May 2025 Abeona Therapeutics enters into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher
  • 29 Apr 2025 Registered for Epidermolysis bullosa dystrophica (In adolescents, In children, In the elderly, In adults) in USA (Topical) - First global approval

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top